Year All202320222021202020192017 Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 1, 2023 Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma January 24, 2023 Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 3, 2023 Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 13 of 13
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma January 24, 2023
